Malignant Teratocarcinosarcoma

A rare neoplasm that involves connective and epithelial tissues and is characterized by large tumors. It often occurs in the nose, pharynx, and sinuses.

Also Known As:

Paranasal sinus teratocarcinosarcoma; Paranasal sinus teratocarcinosarcoma (type); Sinonasal teratocarcinosarcoma; Sinonasal teratocarcinosarcoma (type)

Networked: 19 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Neoplasms (Cancer)
2.	Carcinoma (Carcinomatosis)
3.	Adenocarcinoma
4.	Carcinogenesis
5.	Olfactory Esthesioneuroblastoma (Esthesioneuroblastoma)

Experts

1.	Agaimy, Abbas: 1 article (03/2022)
2.	Cipriani, Nicole A: 1 article (03/2022)
3.	Compton, Margaret L: 1 article (03/2022)
4.	Ely, Kim A: 1 article (03/2022)
5.	Faquin, William C: 1 article (03/2022)
6.	Lewis, James S: 1 article (03/2022)
7.	Shi, Qiuying: 1 article (03/2022)
8.	Belotti, Alessia: 1 article (12/2021)
9.	Bulfamante, Antonio Mario: 1 article (12/2021)
10.	Bulfamante, Gaetano: 1 article (12/2021)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Malignant Teratocarcinosarcoma:

1.	CateninsIBA 08/01/2017 - "Conclusion We identified a potential driver mutation in β-catenin in a sinonasal teratocarcinosarcoma, resulting in β-catenin overexpression. " 08/01/2017 - "Results We identified an activating p.S45F mutation in β-catenin in our index sinonasal teratocarcinosarcoma. " 08/01/2017 - "These findings suggest a role for the Wnt/β-catenin pathway in sinonasal teratocarcinosarcoma tumorigenesis and a role for anti-β-catenin targeted therapy."
2.	beta CateninIBA 03/01/2022 - "SALL-4 and Beta-Catenin Expression in Sinonasal Teratocarcinosarcoma."
3.	Vasopressins (Vasopressin)IBA 03/01/2000 - "Sinonasal teratocarcinosarcoma ("mixed olfactory neuroblastoma-craniopharyngioma") presenting with syndrome of inappropriate secretion of antidiuretic hormone."
4.	Sucrose (Saccharose)IBA 03/01/2023 - "This resulted in a new definition of 4 sinonasal entities driven solely or predominantly by Switch/Sucrose nonfermentable complex deficiency: (1) SMARCB1(INI1)-deficient sinonasal carcinoma (lacking gland formation and frequently displaying a non-descript basaloid, and less frequently eosinophilic/oncocytoid morphology, but no features of other definable subtypes), (2) SMARCB1-deficient sinonasal adenocarcinoma (with unequivocal glands or yolk sac-like pattern), (3) SMARCA4-deficient undifferentiated (sinonasal undifferentiated carcinoma-like) carcinoma (lacking glandular or squamous immunophenotypes), and (4) SMARCA4-deficient subset (~80%) of sinonasal teratocarcinosarcoma. "
5.	Chorionic Gonadotropin (Human Chorionic Gonadotropin)FDA LinkGeneric 08/01/2014 - "A case of a Beta-human chorionic gonadotropin secreting sinonasal teratocarcinosarcoma."
6.	ElementsIBA 07/01/1998 - "Sinonasal teratocarcinosarcoma is very unusual malignant neoplasm histologically consisting of an epithelial element and one or more mesenchymal components. "
7.	Differentiation AntigensIBA 03/01/2022 - "To date, four different SWI/SNF-driven sinonasal tumor types have been recognized: SMARCB1(INI1)-deficient carcinoma (showing frequently non-descript basaloid, and less frequently eosinophilic, oncocytoid or rhabdoid undifferentiated morphology), SMARCB1-deficient adenocarcinomas (showing variable gland formation or yolk sac-like morphology), SMARCA4-deficient carcinoma (lacking any differentiation markers and variably overlapping with large cell neuroendocrine carcinoma and SNUC), and lastly, SMARCA4-deficient sinonasal teratocarcinosarcoma. "

Therapies and Procedures

1.	Radiotherapy 03/01/1995 - "We have presented the first reported case of malignant teratocarcinosarcoma arising in the sphenoid sinus treated successfully with surgery and radiation therapy. " 12/01/2018 - "Surgical excision along with use of postoperative radiotherapy forms an integral management of sinonasal teratocarcinosarcoma (SNTCS). " 12/01/2018 - "Sinonasal teratocarcinosarcoma treated with surgery followed by volumetric modulated radiotherapy: a case report with review of literature." 06/22/2017 - "In cases of sinonasal teratocarcinosarcoma with residual disease post-surgery, radiotherapy alone can be an effective option." 06/22/2017 - "We describe an 83-year-old white woman with sinonasal teratocarcinosarcoma of her left nasal cavity treated with surgical debulking initially with radiological evidence of residual disease which was treated with radiotherapy (60 Gy in 30 fractions). "
2.	Intensity-Modulated Radiotherapy (Radiotherapy, Intensity Modulated) 12/01/2012 - "A case of sinonasal teratocarcinosarcoma treated with surgery and post-operative intensity-modulated radiotherapy (IMRT)." 12/01/2011 - "Intensity-modulated radiotherapy for sinonasal teratocarcinosarcoma."
3.	Therapeutics 12/01/2005 - "Rationale for individualized therapy in Sinonasal Teratocarcinosarcoma (SNTC): case report." 08/01/2017 - "These findings suggest a role for the Wnt/β-catenin pathway in sinonasal teratocarcinosarcoma tumorigenesis and a role for anti-β-catenin targeted therapy."
4.	Proton Therapy 12/01/2021 - "Sinonasal teratocarcinosarcoma treated with surgery and proton beam therapy: clinical, histological aspects and differential diagnosis of a new case."
5.	Neoadjuvant Therapy 10/01/2015 - "Neoadjuvant chemotherapy in advanced sinonasal teratocarcinosarcoma with intracranial extension: Report of two cases with literature review."